Breaking News

Averica Enters Preferred Provider Pact with IRIX

By Kristin Brooks | February 5, 2014

To provide chromatography and analytical services

Averica Discovery Services has expanded its partnership with IRIX Pharmaceuticals to provide services to IRIX on a preferred provider basis. Averica provides chromatography and analytical services, including highly pure assay material. The company has expertise in the isolation and structure elucidation of impurities with its Targeted Isolation process for optimizing chemistry for production of clinical trial materials.
 
“IRIX’s leading position as a supplier of APIs to biotechnology firms and others reflects our scientific excellence, commitment to quality and record of on-time production,” said J. Guy Steenrod, chief executive officer of IRIX Pharmaceuticals. “Leveraging Averica’s capabilities early in the API development process allows our customers to benefit from the most advanced science available. We are pleased to expand this relationship that has been valuable for both companies.”
 
“Our shared commitment to scientific excellence and outstanding customer service provides a strong rationale for extending our relationship with IRIX,” said Jeffrey Kiplinger, Ph.D., president of Averica Discovery Services. “The reduction in timeline and costs delivered by our Targeted Isolation approach is a great example of how our services are helping innovative companies develop new medicines more efficiently.”

Related Contract Manufacturing:

blog comments powered by Disqus
  • API Sourcing Trends

    Kristin Brooks, Contract Pharma||April 11, 2016
    Drug product complexities, quality and regulatory hurdles drive market shift

  • 2015 Contracting & Outsourcing Wrap-up

    2015 Contracting & Outsourcing Wrap-up

    Kristin Brooks, Contract Pharma||September 30, 2015
    A huge success, with another year of record attendance, sold-out exhibit hall, and a great line up of informative sessions

  • Setting a Precedent for Biosimilars in the U.S.

    Setting a Precedent for Biosimilars in the U.S.

    Kristin Brooks, Contract Pharma||May 19, 2015
    Niall Dinwoodie of Charles River discusses several key industry issues on biosimilars and addresses some of the development and regulatory hurdles that remain